BioMarin Pharmaceutical (NASDAQ:BMRN) Upgraded at StockNews.com
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) was upgraded by equities researchers at StockNews.com from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Saturday. Several other brokerages also recently issued reports on BMRN. UBS Group boosted their target price on shares of BioMarin Pharmaceutical from $109.00 to $113.00 […]
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) was upgraded by equities researchers at StockNews.com from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Saturday. Several other brokerages also recently issued reports on BMRN. UBS Group boosted their target price on shares of BioMarin Pharmaceutical from $109.00 to $113.00 […]
